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Valeriana glechomifoliaThe antidepressant-like effect of a supercritical CO2 (SCCO2) Valeriana glechomifolia extract enriched in vale-
potriates was investigated in a mice tail suspension test (TST) and forced swimming test (FST). The SCCO2
extract decreased mice immobility in the FST (0.5–20 mg/kg p.o.) and elicited a biphasic dose–response re-
lationship in the TST (1–20 mg/kg p.o.) with no alterations in locomotor activity and motor coordination
(assessed in the open-ﬁeld and rota-rod tests, respectively). The anti-immobility effect of the SCCO2 extract
(5 mg/kg, p.o.) was prevented by mice pre-treatment with yohimbine (1 mg/kg, i.p., an α2 adrenoceptor an-
tagonist), SCH 23390 (15 μg/kg, s.c., D1 dopamine receptor antagonist) and sulpiride (50 mg/kg, i.p., D2 dopa-
mine receptor antagonist). However, mice pre-treatments with prazosin (1 mg/kg, i.p., α1 adrenoceptor
antagonist) and p-chlorophenilalanine methyl ester (4×100 mg/kg/day, i.p., a serotonin synthesis inhibitor)
were not able to block the anti-immobility effect of the SCCO2 extract. Administration (p.o.) of the SCCO2 ex-
tract (0.25 mg/kg) and imipramine (10 mg/kg), desipramine (5 mg/kg) and bupropion (3 mg/kg) at sub-
effective doses signiﬁcantly reduced mice immobility time in the FST. These data provide the ﬁrst evidence
of the antidepressant-like activity of V. glechomifolia valepotriates, which is due to an interaction with dopa-
minergic and noradrenergic neurotransmission.ced swimming test; i.p., Intra-
nine methyl ester; p.o., Per os;
7-chloro-8-hydroxy-3-methyl-
loride; S.E.M, Standard error
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Depression is a high prevalence mood disorder (Berton and Nestler,
2006) associated with a heavy social burden (Greenberg et al., 2003).
The neurobiology of this disease is still uncompletely understood but
the role of monoaminergic system is accepted (Nutt, 2008). In line
with this, the antidepressants currently available boost the synaptic ac-
tion of one or more of the three monoamines (serotonin, noradrenalin
and dopamine) by blocking the neuronal reuptake of these neurotrans-
mitters (Lambert et al., 2000; Stahl, 2008). Nevertheless, the pharmaco-
therapy employed in the treatment of depression produces several
adverse side effects (Brunello et al., 2002) and a signiﬁcant number of
individuals do not respond to any antidepressant (Berton and Nestler,
2006; Nestler et al., 2002). Thus, there is a need to search for new com-
pounds and strategies of treatment that could improve conventionaltherapies. In this context, natural products research has been consid-
ered as an option for the development of drugs with innovative mech-
anisms of action and/or conceivably minimized adverse side effects
(Wang et al., 2008).
Among alleged neuroactive natural products, Valeriana genus is
widely studied, with special focus on anxiolytic properties (Hattesohl
et al., 2008;Murphy et al., 2010). Besides being themost popular herbal
supplement for the treatment of anxiety and mild sleep disorders, pre-
clinical studies reported the antidepressant-like activity of V. ofﬁcinalis
(Hattesohl et al., 2008), V. wallichii (Sah et al., 2011; Subhan et al.,
2010) and V. prionophylla (Holzmann et al., in press). Moreover, the
clinical efﬁcacy of these species in improving depression symptoms
was also demonstrated (Bhattacharyya et al., 2007).
The molecular mechanisms responsible for these effects have not
been completely elucidated, although some studies point to a stimu-
lation of GABA neurotransmission underlying anxiolytic properties
(Cavadas et al., 1995; Mennini et al., 1993; Ortiz et al., 2004).
Valeriana contains over 135 chemical constituents (Wang et al.,
2010), comprising the volatile oil, ﬂavonoids (Marder et al., 2003)
and valepotriates (epoxy iridoid esters) (Backlund and Moritz,
1998). The identity of bioactive substances is somewhat controversial
but there is evidence that valepotriates substantially contribute to
the pharmacological properties of plants belonging to this genus.
Mennini et al. (1993) demonstrated that diidrovaltrate binds to a bar-
biturate site of a GABAA receptor and, therefore, contributes to the
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Lacher et al. (2007) showed that isovaltrate is a potent inverse ago-
nist of adenosine A1 receptors, which may counteract the desired
sedative effect of the genus. Estrada-Soto et al. (2010) demonstrated
that a hydroalcoholic extract from V. edulis ssp. procera enriched in
valepotriates relaxes isolated rat aorta by blocking calcium channels
and previous reports have shown that isovaltrate and valtrate cause
a suppression of rhythmic contractions in guinea-pig ileum in vivo
and in vitro (Hazelholff et al., 1982). The citotoxic effects of valepotri-
ates in vitro were already demonstrated (Bounthanh et al., 1983; Lin
et al., 2009). However, in vivo experiments have not demonstrated
toxicity in rats orally administered with valepotriates (Tuﬁk et al.,
1994). In summary, literature data regarding the pharmacological ac-
tivity of valepotriates are not very extensive and present some disso-
nant results. Thus, further studies on the central effects of these
compounds are needed.
Among the species native to southern Brazil, V. glechomifolia is the
most studied, and is the only one that accumulates valepotriates in
both aerial and subterranean parts (Silva et al., 2002). Although this
species is not used in traditional medicine, Maurmann et al. (2009)
demonstrated that a valepotriate fraction of V. glechomifolia has sed-
ative and anxiolytic effects and induces alterations in mice recogni-
tion memory. Recently, Bettero et al. (2011) demonstrated that
valtrate, acevaltrate and 1-β-acevaltrate from V. glechomifolia show
inhibitory activity toward Na+ K+ ATPase from rat brain in vitro.
This could be particularly relevant since this enzyme activity is chan-
ged in mood disorders (El-Mallakh and Wyatt, 1995) and the antide-
pressant imipramine also inhibits its activity in rat cortex in vitro
(Zanatta et al., 2001).
Considering that the antidepressant-like effect of V. glechomifoliahas
not been explored yet and central effects of valepotriates are not
completely ascertained, the aim of this study was to investigate the po-
tential antidepressant effect of a SCCO2 V. glechomifolia extract enriched
in valepotriates by using tail suspension and forced swimming tests in
mice, which are animal models used to screen new antidepressant
drugs. The contribution of monoaminergic neurotransmission (seroto-
nergic, noradrenergic and dopaminergic) to the antidepressant-like ef-
fect was also investigated.2. Materials and methods
2.1. Animals
Male CF1 mice (25–30 g) were purchased from Fundação Estadual
de Produção e Pesquisa em Saúde, RS (Brazil). The animals were
housed in plastic cages (17×28×13 cm), ﬁve mice per cage, and
kept under a 12 h light/dark cycle (lights on between 7:00 h and
19:00 h) at constant temperature of 23°±1 °C with free access to
standard certiﬁed rodent diet and tap water. All behavioral experi-
ments were approved by The Animal Care Local Ethical Committee
(CEUA-UFRGS; projects approval number 19022) and performed
according to the European Communities Council Directive of 24 No-
vember 1986 (86/609/EEC). In this study, 570 animals were used. Ex-
cept for rota-rod experiments, all animals were used only once.2.2. Plant material
Plants of V. glechomifolia Meyer (Valerianaceae) were harvested
during its ﬂowering stage, in São José dos Ausentes, Rio Grande do
Sul state, Brazil, in 2009, identiﬁed by Dr. M. Sobral (Universidade
Federal de São João del-Rei, Minas Gerais, Brazil) and a voucher spec-
imen (Sobral, 7733) was deposited in the Herbarium of the Universi-
dade Federal do Rio Grande do Sul (ICN). The plant material was
freeze-dried, powdered and kept frozen until analyzed.2.3. Chemicals and drugs
For the extract characterization, grade HPLC acetonitrile andmetha-
nol were purchased fromMerck® (Germany). For the behavioral exper-
iments, the following drugs were used: ﬂuoxetine, sulpiride and
imipramine hydrochloride from Galena® (Porto Alegre, Brazil), bupro-
pion from Eurofarma® (Brasil) and pCPA, SCH23390, prazosin, yohim-
bine and desipramine which were purchase from Sigma Chemical Co.
(St. Louis, MO, USA). All drugs were dissolved in normal saline and
the extract was suspended in salinewith 1% of polysorbate 80 (vehicle)
prior to use. Drug concentrations in saline solution were: imipramine—
2 mg/ml and 1 mg/ml; ﬂuoxetine—3 mg/ml and 1.5 mg/ml; desipra-
mine—0.5 mg/ml; bupropion—0.3 mg/ml; SCH23390—0.5 mg/ml;
sulpiride—5 mg/ml; prazosin and yohimbine—0.1 mg/ml and pCPA—
10mg/ml. The SCCO2 extract was suspended in vehicle at different
concentrations depending on the dose required: 2 mg/ml, 1 mg/ml,
0.5 mg/ml, 0.1 mg/ml, 0.05 mg/ml and 0.025 mg/ml.
2.4. Supercritical extraction
2.4.1. Apparatus
The supercritical extraction was performed in a Pilot Equipment
(Cassel et al., 2010). The SCCO2 ﬂowed at rate of 6.67×10−4 kg s−1
through the extraction vessel. The extraction vessel was supplied
with a heating jacket and an automated temperature controller, and
heating tapes were used throughout the apparatus to maintain con-
stant temperature in the extraction section. To ensure constant and
steady solvent delivery the pump head was cooled by a circulating
ﬂuid, which passed through a chiller. Flow rates and accumulated
gas volumes passing through the apparatus were measured using a
ﬂowmeter assay, 1–300 g/min (Thar 06618-2, USA). Ke (USA) micro-
metering valves (VC1) were used for ﬂow control throughout the ap-
paratus. Heating tapes with automated temperature control were also
used around this valve to prevent both freezing of the solvents and
solid solute precipitation following depressurization. Pressure in the
extractor was monitored with a digital transducer system, Novus
8800021600, acquired from Novus Produtos Eletrônicos (Brazil)
with a precision of ±1.0 bar. The temperature controller (TC) was
connected to thermocouples (PT-100), with an accuracy of 0.5 K.
2.4.2. Extract preparation
Powdered aerial and underground plant material (120 g dry
weight) was used and the extraction was conducted at constant tem-
perature (40 °C) and pressure (90 bar). The extract was collected
every 30 min and taken to a circulating air oven (40 °C), until the
complete evaporation of the water condensed in the extract due to
Joule–Thompson cooling. The SCCO2 extraction yield recovery was
2.72 g%.
2.5. Determination of diene valepotriates content
Diene valepotriate characterization and quantiﬁcation of the extract
were performed by HPLC analysis, using the method previously validat-
ed by Silva et al. (2002) using a Shimadzu HPLC system (LC-6AD pump,
SPD-20AV UV detector and automatic injector SIL-20 AC). A Waters
Nova-Pack C18 column (4 μm, 3.9×150 mm i.d. with Waters Nova-
Pack C18 guard column, 60 Å, 3.9×20 mm) was the stationary phase;
the mobile phase consisted of acetonitrile and water as isocratic solvent
(50:50 v/v); with a ﬂow rate of 1 mL min−1 and detection at 254 nm.
Valtrate, the valepotriate found in larger quantities in V. glechomifolia,
was used as external standard. For the calibration curve achievement,
valtrate was isolated from the extract through column chromatog-
raphy, with silica gel stationary phase and mobile phase gradient with
n-hexane: dichloromethane. The fractions obtained were monitored by
thin layer chromatography, with standard valtrate, gathered and taken
to dryness in a rotary evaporator. Linearity analysis of the calibration
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mg of valtrate equivalent (VE)/g extract.
2.6. Tail suspension test
The TST was conducted according to Steru et al. (1985) withminor
modiﬁcations (Duarte et al., 2008). Mice were adapted to the labora-
tory conditions 1 h before the exposition to TST. The animals, under
acoustic and visual isolation, were suspended by the tail 60 cm
above the ﬂoor using adhesive tape (1 cm from the tip of the end)
in a dim light room. Immobility time was recorded (in seconds) dur-
ing the last 4 min of a total 6 min session (Kwon et al., 2010). Mice
were considered immobile when they hung passively and completely
motionless. The animals (n=10 per group) were treated orally 1 h
before being submitted to the TST; different groups received vehicle
(10 ml/kg), ﬂuoxetine (30 mg/kg, positive control), SCCO2 extract
from V. glechomifolia (1, 5, 10 and 20 mg/kg). The immobility behav-
ior was recorded by human observers blind to the treatment.
2.7. Forced swimming test
The FST was carried out according to Porsolt et al. (1977) with
minor modiﬁcations standardized and validated in our laboratory
(Viana et al., 2005). Mice were adapted to the laboratory conditions
1 h before being exposed to FST. The animals were individually forced
to swim in a cylinder pool (10 cm diameter, 13 cm height, water at
22°±1 °C) and the total duration of immobility during a 6 min test
was scored (in seconds). Each mouse was recorded as immobile
when it remained ﬂoating motionless or making only the movements
necessary to keep its head above water. The immobility behavior was
recorded by human observers blind to the treatment.
2.7.1. Treatments
Animals (n=8per group)were orally treated (10 ml/kg)with imip-
ramine (20 mg/kg, positive control), SCCO2 extract from V. glechomifolia
(0.25; 0.5; 1; 5; 10; 20 mg/kg) or vehicle, 1 h before being submitted to
the FST.
To access the time-course of the antidepressant-like effect of the
SCCO2 extract from V. glechomifolia (5 mg/kg), the immobility time
in the FST was recorded in independent groups of mice (n=9 per
group), 1, 2 and 3 h after the oral administration of the SCCO2 extract
or vehicle.
The antidepressant-like effect of sub-effective doses of conven-
tional antidepressants combined with a sub-effective dose of the
SCCO2 extract was also investigated. For this purpose, mice (n=8–
10 per group) were orally treated with imipramine (10 mg/kg, a nor-
adrenaline and serotonin reuptake inhibitor), desipramine (5 mg/kg,
a noradrenaline reuptake inhibitor), bupropion (3 mg/kg, a dopamine
reuptake inhibitor) or ﬂuoxetine (15 mg/kg, a serotonin reuptake in-
hibitor) and immediately after, a sub-effective dose of the SCCO2 ex-
tract (0.25 mg/kg p.o.) or vehicle was administered. After 1 h, the
FST was carried out.
In order to assess the possible involvement of the noradrenergic
neurotransmission on the antidepressant-like effect of the SCCO2 ex-
tract in the FST,mice (n=8–10 per group)were pretreatedwith prazo-
sin (1 mg/kg, i.p., an α1 adrenoceptor antagonist); yohimbine
(1 mg/kg, i.p., an α2 adrenoceptor antagonist) or vehicle. After 30 min
they received the SCCO2 extract (5 mg/kg, p.o.) or vehicle, and were
submitted to the FST 1 h later.
The contribution of the dopaminergic neurotransmission to the
antidepressant-like effect of the SCCO2 extract was evaluated by
using dopamine receptor antagonists. Animals (n=8–10 per group)
were pretreated with sulpiride (50 mg/kg, i.p., a D2 antagonist) or
SCH 23390 (15 μg/kg, s.c., a D1 antagonist) 30 min before the admin-
istration of the SCCO2 extract (5 mg/kg p.o.). One hour later, the ani-
mals were submitted to the FST.For evaluating the serotonergic neurotransmission, mice (n=8–
12 per group) were pretreated with pCPA (100 mg/kg, i.p., an inhibi-
tor of serotonin synthesis) or saline, once a day, for 4 consecutive
days. Twenty-four hours after the last pCPA or saline injection, ani-
mals were treated with the SCCO2 extract (5 mg/kg, p.o.), or vehicle
and were tested in the FST 1 h later.
The drug doses were chosen on the basis of previous results
obtained by our research group (Viana et al., 2005) and on literature
data (Jesse et al., 2010; Wang et al., 2008).
2.8. Open-ﬁeld test
The OFT was performed in order to evaluate the possible effects of
the SCCO2 extract as well as its association with antidepressant sub-
effective doses on the locomotor and exploratory activities. For this
purpose, mice (n=10–12) received those treatments that signiﬁ-
cantly reduced the immobility time in FST 1 h before being observed
in the open-ﬁeld. Animals were individually placed in an acrylic box
(40×30×30 cm), with the ﬂoor divided into 24 equal squares. After
the habituation to the arena for 5 min, the number of squares crossed
with the four paws (crossing) and rearing was recorded in a 15 min
session, by human observers blind to the treatment. The apparatus
was cleaned with 10% ethanol after each mouse exposition.
2.9. Rota-rod test
The rota-rod test was carried out to assess the possible effects of
the SCCO2 extract on the integrity of mice motor coordination as de-
scribed by Neves et al. (2010). The apparatus consisted of a cylinder
of 3 cm of diameter rotating at 5 rpm. Initially, the animals were indi-
vidually habituated to the apparatus for 5 min. Twenty four hours
later, the animals were trained for 5 min and only the ones that
were able to stay balanced on the rotating rod for 90 s were selected
for testing. Immediately after, mice were orally treated with the
SCCO2 extract (0.5; 5 and 20 mg/kg) or vehicle. One hour later, mice
performance in the rota-rod was evaluated by human observers
blind to the treatment, considering the longest time of permanence
on the apparatus and the number of falls, in a 5 min period.
2.10. Statistical analysis
Results obtained in the FST, TST and OFT were analyzed by one or
two-way ANOVA followed by Student–Newman–Keuls test when ap-
propriate. Rota-rod test results were analyzed by two-way ANOVA
with repeated measures (being the treatment the ﬁrst factor and
the session, second factor, the repeated-measure). The level for statis-
tical signiﬁcance was set as pb0.05. The statistical procedures were
performed using the Sigma Stat software 2.03 (Jandel Scientiﬁc
Corporation).
3. Results
3.1. Diene valepotriates from SCCO2 V. glechomifolia extract
Diene valepotriates content from the SCCO2 extract determined by
HPLC analysis is shown in Table 1 and each valepotriate chemical struc-
ture is presented in Fig. 1. The valepotriate found in larger quantity was
valtrate (474.23 mg/g), followed by acevaltrate (173.09 mg/g), 1-β-
acevaltrate (55.3 mg/g), 1-β-aceacevaltrate (37.57 mg/g) and isoval-
trate (32.68 mg/g).
3.2. Antidepressant-like effect in the TST and FST
The effects of the SCCO2 extract acute administration in the FST and
TST are shown in Fig. 2A and B, respectively. One-way ANOVA revealed
a signiﬁcantmain effect of the SCCO2 extract in the FST [F(7,55)=12.98;
Table 1
Diene valepotriate content (mg/g extract) of the supercritical CO2 V. glechomifolia
extract determined through HPLC.
Valepotriate Concentration (mg/g extract)
Valtrate 474.23±4.06
Acevaltrate 173.09±3.17
1-β-Acevaltrate 55.30±0.25
1-β-Aceacevaltrate 37.57±0.15
Isovaltrate 32.68±0.45
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mice immobility time caused by the positive control imipramine
(pb0.001) and SCCO2 extract administration at 0.5 (pb0.05), 1, 5, 10
and 20mg/kg (pb0.001) when compared to vehicle-treated group. In
addition, the immobility time of mice that were administered with
SCCO2 extract 0.5 mg/kgwas signiﬁcantly higher (pb0.05) than the im-
mobility time of the groups that received the SCCO2 extract at 1–
20 mg/kg, characterizing a dose–response relationship.
One-way ANOVA revealed a signiﬁcant main effect of the SCCO2
extract [F(5,59)=5.71; pb0.001] in the TST (Fig. 2B). Post hoc analy-
sis indicated a signiﬁcant decrease in the immobility time elicited by
the administration of the SCCO2 extract at doses of 5 (pb0.05) and
10 mg/kg (pb0.01) and the positive control ﬂuoxetine at 30 mg/kg
(pb0.001), when compared with vehicle-treated group. SCCO2 ex-
tract did not show any anti-immobility effect in the TST at the lowestFig. 1. Diene valepotriates(1 mg/kg) and highest (20 mg/kg) tested doses, indicating a bell-
shaped dose–response relationship.
A time-course analysis of the antidepressant-like effect of the SCCO2
extractwas accomplished in the FST (Fig. 3). The antidepressant-like ac-
tivity of the SCCO2 extract reached its peak in 1 h, remained signiﬁcant
up to 2 h [one-way ANOVA: F(3,35)=24.12; pb0.001] and this effect
was abolished 3 h after treating. The administration of the SCCO2 ex-
tract (0.5; 5 and 20 mg/kg) did not alter the locomotor activity in OFT
neither the motor coordination integrity assessed by the rota-rod test
(Table 2). Considering these results, the time point of 1 h and the dose
of 5 mg/kg were chosen for all further experiments. Also, the SCCO2 ex-
tract sub-effective dose of 0.25 mg/kg was selected to be employed in
combination with antidepressant sub-effective doses in the FST.
3.3. Interaction of the SCCO2 extract with antidepressants in the FST
Fig. 4 depicts the results obtained by the combined administration
of sub-effective doses of the conventional antidepressants with the
SCCO2 extract.
Imipramine, administered at a sub-effective dose (10 mg/kg, p.o.),
associated with a sub-effective dose of SCCO2 (0.25 mg/kg, p.o.) ex-
tract reduced the immobility time of mice submitted to the FST as
compared to vehicle-treated group (47.3% of reduction) [one-way
ANOVA: F(3,34)=10.28; pb0.001] (Fig. 4A).
Likewise, the co-administration of sub-effective doses of desipra-
mine (5 mg/kg, p.o.) and SCCO2 extract (0.25 mg/kg p.o.) elicited anfrom V. glechomifolia.
Fig. 2. Effect of acute administration of imipramine 20 mg/kg, p.o. (IMI), ﬂuoxetine
30 mg/kg p.o. (FLU) and SCCO2 extract in mice FST (panel A) and TST (panel B). Each
column represents the mean±SEM (n=8–10 mice/group). One-way ANOVA followed
by Student–Newman–Keuls: *pb0.05 **pb0.01 and ***pb0.001 when compared to the
respective vehicle-treated group (SAL); #pb0.05, ##pb0.01 when compared to the
group SCCO2 extract 0.5 mg/kg.
105L.G. Müller et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 36 (2012) 101–109antidepressant-like effect in the FST (35% of reduction in immobility
time) [one-way ANOVA: F(3, 35)=8.84; pb0.001] (Fig. 4B).
Fig. 4C shows that the effect of bupropion at a sub-effective dose
(3 mg/kg, p.o.) was ampliﬁed when it was associated with a sub-
effective dose of the SCCO2 extract (0.25 mg/kg, p.o.) in the FST (38.8%
of reduction in the immobility time) [one-way ANOVA: F(3,35)=
11.11; pb0.001].
The combination of a sub-effective dose of ﬂuoxetine (15 mg/kg,
p.o) with the SCCO2 extract sub-effective dose did not elicit any
antidepressant-like effect in the FST (one way ANOVA: F(3,35)=0.85;
p=0.475] (Fig. 4D).
The association of all antidepressant drugs tested with SCCO2 ex-
tract did not affect locomotor and exploratory activities assessed in
the OFT (Table 2).Fig. 3. Time-course of the antidepressant-like effect of the SCCO2 extract (5 mg/kg, p.o.)
in mice FST. The SCCO2 extract was administered 1, 2 or 3 h before the FST. Each col-
umn represents the mean±SEM (n=9 mice/group). One-way ANOVA followed by
Student–Newman–Keuls: ***pb0.001 when compared to the vehicle-treated group
(SAL).3.4. Involvement of noradrenergic neurotransmission in the
antidepressant-like effect of the SCCO2 extract in the FST
Fig. 5A shows that the pretreatment of mice with yohimbine
(1 mg/kg, i.p.) was able to prevent the anti-immobility effect eli-
cited by the SCCO2 extract (5 mg/kg, p.o.) in the FST. Two-way
ANOVA revealed a signiﬁcant main effect of yohimbine pretreat-
ment [F(1,31)=9.65; pb0.01], SCCO2 extract [F(1,31)=12.56;
pb0.001] and yohimbine×SCCO2 extract interaction [F(1,31)=
5.99; pb0.05]. Fig. 5B shows that the pretreatment of mice with
prazosin (1 mg/kg, i.p.) did not prevent the anti-immobility effect
of the SCCO2 extract in the FST. Two-way ANOVA revealed a signif-
icant main effect of the SCCO2 extract [F(1,33)=83.603; pb0.001],
but not of prazosin pretreatment [F(1,33)=1.25; p=0.27], nor
prazosin×SCCO2 extract interaction [F(1,33)=0.867; p=0.36].
3.5. Involvement of dopaminergic neurotransmission in the
antidepressant-like effect of the SCCO2 extract in the FST
The results depicted in Fig. 5C show that the pretreatment of
mice with SCH 23390 (15 μg/kg, s.c.) signiﬁcantly prevented the
antidepressant-like effect of the SCCO2 extract in the FST. Two-way
ANOVA revealed a signiﬁcant main effect of SCH 23390 pretreatment
[F(1,32)=7.06; pb0.05], SCCO2 extract [F(1,32)=18.06; pb0.001]
and SCH 23390×SCCO2 extract interaction [F(1,32)=4.64; pb0.05].
The pretreatment of mice with sulpiride (50 mg/kg, i.p., Fig. 5D)
was also able to prevent the anti-immobility effect of the SCCO2 ex-
tract. Two-way ANOVA revealed a signiﬁcant main effect of sulpiride
[F(1,31)=13.99; pb0.001], SCCO2 extract [F(1,31)=10.67; pb0.01]
and sulpiride×SCCO2 interaction [F(1,31)=11.93; pb0.01].
3.6. Involvement of serotonergic neurotransmission in the
antidepressant-like effect of the SCCO2 extract in the FST
The pretreatment of mice with pCPA (100 mg/kg, i.p., once a day
for 4 consecutive days) was not able to prevent the effect of the
SCCO2 extract on the FST (Fig. 5E). Two-way ANOVA did not reveal
a main effect of pCPA pretreatment [F(1,34)=2.50; p=0.123] nor a
pCPA×SCCO2 extract interaction [F(1,34)=0.14; P=0.71], but a sig-
niﬁcant main effect of the SCCO2 extract [F(1,34)=18.83; pb0.001].
4. Discussion
In the present study we have shown for the ﬁrst time, to our
knowledge, the antidepressant-like effect of a SCCO2 V. glechomifolia
extract enriched in valepotriates in both TST and FST, which are pre-
dictive of antidepressant activity (Bourin et al., 2005). This effect was
not related to a non-speciﬁc behavioral alteration, given that the
SCCO2 extract did not alter locomotor activity or motor coordination.
Furthermore, it was demonstrated that SCCO2 extract antidepressant-
like effect seems to be mediated by an interaction with the dopami-
nergic and noradrenergic neurotransmission, but not with the seroto-
nergic neurotransmission. These ﬁndings are in accordance to Sah et
al. (2011) that reported the antidepressant-like effect of a V. wallichii
dichloromethane extract (containing mainly valepotriates) in mice
FST, which is mediated by noradrenergic and dopaminergic neuro-
transmission, with no signiﬁcant dependence on the serotonergic
neurotransmission.
The antidepressant-like effect of the SCCO2 extract was more pro-
nounced in the FST in comparison to the TST, since the SCCO2 extract
at 0.5 mg/kg signiﬁcantly reduced the immobility time of the animals
in the FST, whereas this effect was observed only at 5 mg/kg in the
TST, where a bell-shaped dose–response relationship was found. Al-
though both TST and FST are alike in some aspects, they have differ-
ences involving the substrates and neurochemical pathways that are
related to the performance on these tests (Bai et al., 2001). The TST
Table 2
Locomotor activity (open ﬁeld test) and motor coordination (rota-rod test) of mice (n=10–12) orally treated with V. glechomifolia SCCO2 extract or subeffective doses of the SCCO2
extract and conventional antidepressants.
Treatment Open ﬁeld Rota-rod
Crossingsa Rearingsa Permanence time (s)b Number of fallsb
Training Test Training Test
Vehicle 291±48 93±10 257±11 246±17 0.7±0.3 1.3±0.5
SCCO2 extract 0.5 mg/kg 269±39 104±17 265±18 290±19 0.5±0.3 0.7±0.5
SCCO2 extract 5 mg/kg 282±49 99±15 266±20 231±30 1.5±0.5 1.4±0.8
SCCO2 extract 20 mg/kg 313±42 105±12 244±20 240±32 1.2±0.6 1.8±1
SCCO2 extract 0.25 mg/kg+imipramine 10 mg/kg 283±53 88±11
SCCO2 extract 0.25 mg/kg+desipramine 5 mg/kg 302±38 101±14
SCCO2 extract 0.25 mg/kg+bupropion 3 mg/kg 284±44 82±19
SCCO2 extract 0.25 mg/kg+ﬂuoxetine 15 mg/kg 316±46 90±13
a Data are expressed as Mean±S.E.M. Results were analyzed by One-Way ANOVA.
b Data are expressed as Mean±S.E.M. Results were analyzed by two-way repeated measures ANOVA.
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ly on the serotonergic neurotransmission, since this test is more sen-
sitive than the FST to these drugs (Cryan et al., 2005; Porsolt et al.,
1991). Hence, the less pronounced action of the SCCO2 extract on
the TST suggests that serotonergic neurotransmission is not impor-
tant for its effect. This hypothesis was supported by our subsequent
experiments.
Our results demonstrated that the anti-immobility effect of the
SCCO2 extract on the FST was completely prevented by pretreatment
with yohimbine, SCH 23390 and sulpiride whereas pretreatment with
pCPA was not able to prevent it, indicating that the effect of the SCCO2
extract depends mainly on noradrenergic (viaα2 receptor) and dopa-
minergic (via D1 and D2 receptors) neurotransmission.
Literature data show the involvement of α2 adrenoceptor and do-
paminergic receptors in the action of some antidepressants (Gherson
et al., 2007; Paparrigopoulos et al., 2001; Porcelli et al., 2011): D1Fig. 4. Effect of the administration of a sub-effective dose of the SCCO2 extract (0.25 mg/kg
(5 mg/kg, p.o., panel B), bupropion (3 mg/kg, p.o., panel C) and ﬂuoxetine (15 mg/kg, p.o., p
One-way ANOVA followed by Student–Newman–Keuls: ***pb0.001 when compared to vehand D2 receptor agonists, as well as drugs that increase dopamine
function, have an antidepressant-like proﬁle in patients and animal
models of depression (D'Aquila et al., 2000; Picillo et al., 2010; Sato
et al., 2010); O'Neill and Conway (2001) demonstrated that the
antidepressant-like effect of clonidine (α2 adrenoceptor agonist) in
the FST was prevented by the pretreatment with yohimbine.
The SCCO2 extract was able to potentiate the effect of the conven-
tional antidepressants imipramine, desipramine and bupropion in FST,
with no behavioral stimulation, whereas the combined administration
of the SCCO2 extract and ﬂuoxetine did not produce any anti-
immobility effect corroborating with the hypothesis that the serotoner-
gic neurotransmission is not directly involved in the mode of action of
the SCCO2 extract and pointing to the activation of noradrenergic and
dopaminergic neurotransmitter systems. Considering that postsynaptic
α2 adrenoceptors play an important role in desipramine antidepressant
effects (Zhang et al., 2009) and mice pre-treatment with yohimbine, p.o.) with a sub-effective dose of imipramine (10 mg/kg, p.o., panel A), desipramine
anel D) in mice FST. Each column represents the mean±SEM (n=8–10 mice/group).
icle-treated group (SAL).
Fig. 5. Effect of pretreatment of mice with yohimbine (1 mg/kg, p.o., panel A), prazosin (1 mg/kg, p.o., panel B), SCH 23390 (15 μg/kg, s.c., panel C), sulpiride (50 mg/kg, i.p., panel D)
and pCPA (100 mg/kg/day, i.p., panel E) on the anti-immobility effect of the SCCO2 extract (5 mg/kg, p.o.) in the FST. Each column represents the mean±S.E.M (n=8–12
mice/group). Two-way ANOVA followed by Student–Newman–Keuls: **pb0.01 ***pb0.001 when compared to the vehicle-treated group.
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may infer that these postsynaptic receptors are involved in the
antidepressant-like effect of the SCCO2 extract.
Altogether the results from our study suggest that the SCCO2 ex-
tract presents a dual-action distinct frommost of the conventional an-
tidepressants. Novel agents with multiple and distinct therapeutic
mechanisms are needed since they may show a good response in se-
lective serotonin reuptake inhibitor (SSRI)-resistant patients (Fava,
2000; Ruhé et al., 2006). Currently, the most frequently prescribed
class of dual-action antidepressants is serotonin–norepinephrine re-
uptake inhibitors (SNRIs) such as venlafaxine, duloxetine andmilnaci-
pram, which increase the levels of both neurotransmitters within the
central nervous system by selectively inhibiting their reuptake in the
synaptic clefts (Stahl, 2008). Nevertheless, there are depressed pa-
tients (especially those not responding to standard SSRIs and SNRIs)
that require treatment with more powerful dopaminergic effects,
since these drugs may improve residual symptoms related to a deﬁ-
ciency in the mesolimbic dopamine system, including impaired moti-
vation, concentration, and pleasure (Dunlop and Nemeroff, 2007).
Moreover, there are converging evidence demonstrating that com-
pounds acting on the noradrenergic neurotransmission are more ef-
fective in the treatment of severe depression than those with an
exclusive serotonergic mechanism (Brunello et al., 2002; Dell'Ossoet al., 2010). Currently, the prototypical agent of dual-action norad-
renergic and dopaminergic antidepressants is bupropion, which has
proven to be a useful antidepressant for the treatment of SSRI or
SNRI-resistant depression (Baumann, 2007). Considering these litera-
ture data, the dual-action of the SCCO2 extract observed here point to
valepotriates as promising agents for developing new antidepressants
to treat those patients for whom the serotonergic action is not enough.
Furthermore we can suggest that the combination of SCCO2 V. gle-
chomifolia extract as well as other Valeriana species with conventional
antidepressants may be a promising approach for further studies on
the treatment of depression. Some authors have been considering the
adjuvant use of herbal medicines valuable to enhance the response
and improve efﬁcacy of synthetic antidepressants and decrease their
side-effects by allowing lower doses to be prescribed (Sarris et al.,
2010). In fact, in several cases the antidepressant pharmacotherapy is
poorly tolerated due to the adverse side effects of conventional drugs,
which include sexual dysfunction, insomnia, gastrointestinal disorders,
hypotension and dizziness (Berton and Nestler, 2006). Combining anti-
depressants from different classes represents an alternative strategy to
exploit potential synergies among two or more independent therapeu-
tic mechanisms for treating refractory patients. The main advantage of
this approach is decreased doses of antidepressants prescribed and con-
sequently the adverse side effects (Lam et al., 2002).
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In conclusion, the results obtained in this study provided the ﬁrst
evidence of the antidepressant-like effect of V. glechomifolia and indi-
cate the valepotriates as new promising chemical entities for devel-
oping new antidepressant drugs. It was shown that this effect is
mediated by dopaminergic (D1 and D2 receptors) and noradrenergic
(α2 receptor) neurotransmission, which represents a dual-action dif-
ferent from most of the available antidepressants. Further studies are
in progress to determine which valepotriates are responsible for the
antidepressant-like activity of SCCO2 V. glechomifolia extract as well
as to elucidate their molecular target.
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